Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts
1. BMY's Q4 revenue reached $12.34 billion, exceeding expectations. 2. Sales rose 8% year-over-year, driven by Growth Portfolio and Eliquis demand. 3. Opdivo and Orencia sales increased, while legacy portfolio revenues declined. 4. Guidance suggests 2025 EPS will fall short of consensus estimates. 5. BMY implemented $2 billion cost-saving initiatives to enhance productivity.